N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide( MK 0364)
| Title | Journal |
|---|---|
| Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. | Journal of clinical psychopharmacology 20120801 |
| [The pharmacological treatment of obesity: past, present and future]. | Orvosi hetilap 20120311 |
| Structure-activity relationship studies of novel pyrazole and imidazole carboxamides as cannabinoid-1 (CB1) antagonists. | Bioorganic & medicinal chemistry letters 20110815 |
| Binding properties of antagonists to cannabinoid receptors in intact cells. | Fundamental & clinical pharmacology 20110401 |
| Cannabinoid type 1 receptor antagonists for smoking cessation. | The Cochrane database of systematic reviews 20110316 |
| A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. | Obesity (Silver Spring, Md.) 20101201 |
| Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist. | The AAPS journal 20101201 |
| Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans. | Xenobiotica; the fate of foreign compounds in biological systems 20101001 |
| In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys. | Xenobiotica; the fate of foreign compounds in biological systems 20100901 |
| Discovery of 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2-chlorophenyl)-1H-pyrazol-3-yl)-5-tert-butyl-1,3,4-thiadiazole (GCC2680) as a potent, selective and orally efficacious cannabinoid-1 receptor antagonist. | Bioorganic & medicinal chemistry 20100901 |
| Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant. | Bioorganic & medicinal chemistry letters 20100815 |
| A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. | International journal of obesity (2005) 20100801 |
| Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. | Bioorganic & medicinal chemistry letters 20100615 |
| A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. | Diabetes, obesity & metabolism 20100601 |
| Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity. | Journal of medicinal chemistry 20100527 |
| A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. | International journal of obesity (2005) 20100501 |
| Randomized, controlled, double-blind trial of taranabant for smoking cessation. | Psychopharmacology 20100401 |
| Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. | Journal of neurochemistry 20100301 |
| Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: synthesis and biological evaluation. Part 1. | Bioorganic & medicinal chemistry letters 20100215 |
| Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work? | Cardiovascular research 20091201 |
| Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist. | Journal of clinical pharmacology 20091001 |
| Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. | International journal of obesity (2005) 20090901 |
| Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists. | Bioorganic & medicinal chemistry letters 20090901 |
| Discovery and functional evaluation of diverse novel human CB(1) receptor ligands. | Bioorganic & medicinal chemistry letters 20090801 |
| Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists. | Journal of medicinal chemistry 20090723 |
| Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation. | Bioorganic & medicinal chemistry letters 20090501 |
| Identification and structural elucidation of process impurities generated in the end-game synthesis of taranabant (MK-0364) via cyanuric chloride. | Journal of pharmaceutical and biomedical analysis 20090405 |
| Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist. | Advances in therapy 20090201 |
| Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics. | Journal of clinical pharmacology 20090101 |
| PET imaging studies in rhesus monkey with the cannabinoid-1 (CB1) receptor ligand [11C]CB-119. | Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 20090101 |
| Feeding disorders and obesity. | Current topics in behavioral neurosciences 20090101 |
| Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. | Journal of medicinal chemistry 20081127 |
| Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin. | Advances in therapy 20081101 |
| Taranabant, a novel cannabinoid type 1 receptor inverse agonist. | Current opinion in investigational drugs (London, England : 2000) 20081001 |
| The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. | Archiv der Pharmazie 20080701 |
| Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. | Journal of clinical pharmacology 20080601 |
| Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist. | Journal of medicinal chemistry 20080410 |
| Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity. | Journal of medicinal chemistry 20080410 |
| Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. | Journal of clinical pharmacology 20080401 |
| Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies? | Cell metabolism 20080101 |
| The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. | Cell metabolism 20080101 |
| The endocannabinoid system as a target for obesity treatment. | Clinical cornerstone 20080101 |
| Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use. | Journal of medicinal chemistry 20070726 |
| Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. | The Journal of pharmacology and experimental therapeutics 20070601 |
| Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. | Journal of medicinal chemistry 20061228 |